Pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate,
have been used for more than half a century in the therapy of the parasitic disease …

Many first-line treatments for neglected tropical diseases identified by the World Health
Organization (WHO) are limited by one or more of the following: the development of drug …

The development of an effective oral therapeutics is an immediate need for the control and
elimination of visceral leishmaniasis (VL). We exemplify the preparation and optimization of …

Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and
development. Most antileishmanial drugs are highly toxic, present resistance issues or …

Eighteen analogues of an active natural chalcone were synthesized using xanthoxyline and
some derivatives, and these analogues were tested for selective activity against both …

Leishmaniasis causes significant morbidity and mortality and thus constitutes a serious
public health problem. Even though it has long been endemic in developing countries, in …

Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement
and fatal systemic infection. WHO estimates that the disease results in 2 million new cases a …

Abstract Objectives Meglumine antimoniate (MA; Glucantime®), the 80‐year‐old first‐line
systemic treatment for all forms of American tegumentary leishmaniasis (ATL) caused by …

The lack of effective vaccines and the development of resistance to the current treatments
highlight the urgent need for new anti-leishmanials. Sphingolipid metabolism has been …

Leishmaniasis is a parasitic disease that threatens 350 million people worldwide. In a
search for new antileishmanial drugs, the in vitro activity of flavonoids from Kalanchoe …